Corporate
-
Announcements
Marketing
-
New Products & Services
Ranbaxy unveils 2 urology products
Our Bureau
Advertisement
|
|
New Delhi
Jan. 29
Ranbaxy Laboratories has announced the launch of two urology products — Niftran capsules and Eligard — in the domestic market.
The two differentiated, Novel Drug Delivery System (NDDS) products — Niftran 100 mg capsules (Nitrofurantoin modified release) developed using the company's R&D capabilities and Eligard 22.5 mg and 45 mg (Leuprolide Depot) that has been in-licensed from QLT Inc, USA — have been launched in the domestic market, the company said in a release.
"The launch reinforces our commitment in NDDS segment and further consolidates our leadership position. The drugs augment our urology franchise helping customers by offering superior options and convenience," Ranbaxy's Senior Vice-President and Regional Director (Asia and CIS), Mr Sanjeev I. Dani, said.
Niftran offers better patient compliance due to twice-a-day dosage compared to the conventional four times-a-day dosage with the currently available Nitrofurantoin in the market, the statement said.
Eligard is used for advanced prostate cancer and is also an NDDS-based hormonal therapy product, it said.
More Stories on :
Announcements |
New Products & Services |
Ranbaxy Laboratories Ltd |
Pharmaceuticals |
Health
Article
E-Mail
::
Comment
::
Syndication
::
Printer Friendly Page
|
